News & Events about Bristol Myers Squibb Co.
NORTHAMPTON, MA / ACCESSWIRE / January 27, 2023 / Originally published on Bristol Myers Squibb News & PerspectivesA decade ago, the evolution of immuno-oncology transformed the landscape of therapy for patients with many cancers. Although individual immunotherapies have helped to improve...
Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Reblozyl (luspatercept) as a treatment for adult patients with anemia associated with nontransfusion-dependent (NTD) beta...
Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis. Sotyktu, an oral...
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: ...
Amgen Joins Gilead Sciences as a Program SupporterApplications Now Open for Physicians and Medical StudentsOriginally published on Bristol Myers Squibb News & PerspectivesPRINCETON, NJ / ACCESSWIRE / January 19, 2023 / The Robert A. Winn Diversity in Clinical Trials Award Program (Winn...